两种细胞因子受体在胰腺癌中的表达及临床应用价值  

Expression and clinical significance of hepatocyte growth factor receptor and epidermal growth factor receptor in pancreatic cancer

作　　者：卢庆乐[1] 田玫玲[1] 芦珂[1] 张莹[1] 

机构地区：[1]山东大学附属省立医院检验科,山东济南250022

出　　处：《检验医学与临床》2013年第17期2217-2219,共3页Laboratory Medicine and Clinic

摘　　要：目的探讨胰腺癌组织中表皮生长因子受体(EGFR)和肝细胞生长因子受体(Met)基因和蛋白的表达情况,及其与胰腺癌临床病理特征和预后的关系。方法采用免疫组化法检测78例胰腺癌组织和23例正常胰腺组织中EGFR和Met蛋白的表达情况,采用实时定量聚合酶链反应(RT-RCR)法检测EGFR和Met-DNA的相对拷贝数。结果 78例胰腺癌组织中,EGFR和Met蛋白的阳性表达率明显高于正常胰腺组织,差异均有统计学意义(P<0.05)。肿瘤直径大于4cm患者、胰腺癌组织高中分化患者、出现远处转移患者、淋巴转移患者、肠系膜上血管侵犯患者、TNM分期为Ⅲ和Ⅳ期患者中EGFR和Met蛋白的表达均明显高于肿瘤直径小于或等于4cm患者,胰腺癌组织低分化患者,未出现远处转移患者、未有淋巴转移患者、未出现肠系膜上血管侵犯患者、TNM分期为Ⅰ和Ⅱ期患者,差异具有统计学意义(P<0.05)。胰腺癌患者中,EGFR和Met-DNA相对拷贝数均明显高于正常胰腺组织中EGFR和Met-DNA相对拷贝数,差异具有统计学意义(P<0.05)。高表达EGFR和Met胰腺癌患者的平均生存时间均显著低于Met及EGFR低表达患者,差异具有统计学意义(P<0.05)。Met和EGFR均高表达的患者的平均生存时间较Met或EGFR单一高表达者的短,差异具有统计学意义(P<0.05)。结论 EGFR和Met的表达与胰腺癌的临床病理相关指标密切相关,对二者的分析研究有助于对胰腺癌患者的预后作出预测,并对化疗药物新靶点筛选提供理论依据。Objective To study the clinical significance of hepatocyte growth factor receptor （Met） and epidermal growth factor receptor（EGFR） in pancreatic cancer. Methods Expression levels of EGFR and Met protein were detected by immunohistochemical staining in 78 cases of pancreatic cancer tissues and 23 cases of normal pancreatic tissues, and gene copy numbers of EGFR and Met were detected by fluorescent real time-polymerase chain reaction. Results Positive rates of EGFR and Met expression in pancreatic cancer tissues were higher than those in normal tissues （P〈0.05）. Expression levels of EGFR and Met were significantly influenced by TNM stages, tumor size, su- perior mesenteric vessels invasion and transfer of tumor lesions （P〈0.05）. Relative gene copy numbers of EGFR and Met in pancreatic cancer tissues were significantly higher than those in normal pancreatic tissues （P〈0.05）. The median survival time of pancreatic Cancer patients with high expression of EGFR or Met were significantly lower than patients with low expression of Met or EGFR （P〈0.05）. The median survival time of patients with high ex- pression of Met and EGFR were significantly lower than patients with high expression of Met or EGFR （P〈0.05）. Conclusion EGFR and Met might interact in a synergistic manner with the oncogenesis and development of pancreatic cancer, could be helpful for the prognostic evaluation of pancreatic cancer and also could be new therapeutic targets in pancreatic cancer.

关 键 词：胰腺癌 表皮生长因子受体 肝细胞生长因子受体 实时定量聚合酶链反应 免疫组织化学 

分 类 号：R735.902[医药卫生—肿瘤]